Market Overview

UPDATE: Goldman Sachs Cuts PT to $4.60 on ZELTIQ Aesthetics Following Q4 Results

Related ZLTQ
Benzinga's Top Upgrades, Downgrades For February 14, 2017
Wall Street's M&A Chatter From February 13

Goldman Sachs reiterated its Neutral rating on ZELTIQ Aesthetics (NASDAQ: ZLTQ) and reduced its price target from $5 to $4.60.

Goldman Sachs noted, "Zeltiq announced preliminary 4Q2012 results that were well below our estimates and consensus. … Zeltiq is still trying to figure out its go-to-market strategy and how to target the most appropriate customer. We think this lack of strategic direction over the past two quarters has been the primary culprit of poor sales execution. We also see competitive pressures (especially Solta's LipoSonix product) as having impacted results, a trend that should remain a headwind for the foreseeable future."

ZELTIQ Aesthetics closed at $4.74 on Friday.

Latest Ratings for ZLTQ

Feb 2017Leerink SwannDowngradesOutperformMarket Perform
Feb 2017Aegis CapitalDowngradesBuyHold
Feb 2017Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for ZLTQ
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (ZLTQ)

View Comments and Join the Discussion!

Partner Center